Kinnate Biopharma Receives Fast Track Designation From The U.S. FDA For KIN-2787, An Investigational Pan-RAF Inhibitor
SAN FRANCISCO and SAN DIEGO, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (NASDAQ:KNTE) ("Kinnate"), a clinical-stage precision oncology company, today announced that the U.S. Food and Drug